Sansure Biotech Inc. (688289.SH) plans to acquire 100% equity of Zhongshan Haiji for 808 million yuan. Its main product is human growth hormone.

Sansure Biotech Inc. (688289.SH) announced that the company plans to acquire 100% equity of Zhongshan Weiming Haiji Biopharmaceutical Co., Ltd. (referred to as "Zhongshan Haiji") for RMB 807.5 million. After the completion of the transaction, Zhongshan Haiji will become a wholly-owned subsidiary of the company. The target company of this transaction has been engaged in the research and production of recombinant gene products and biological products, with its main products being human growth hormone (short-acting powder injection, short-acting water injection). The announcement stated that Zhongshan Haiji has a certain production capacity in recombinant protein, peptide technology platform, as well as overall industrial microbiology and synthetic biology, which can collaborate with the company to develop synergies in the field of functional biomedical products. The company will continue to provide technical support and collaborative innovation for the ongoing human growth hormone research project based on the strengths of both parties. The professional capabilities in the diagnostic testing field can also provide necessary verification and feedback support for the continuous optimization and iteration of human growth hormone products.